These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 16339608)
1. Should the CATIE study be a wake-up call? Ragins M Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608 [No Abstract] [Full Text] [Related]
2. The CATIE study and its implications for antipsychotic drug use. Janicak PG Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293 [No Abstract] [Full Text] [Related]
3. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Kane JM J Clin Psychiatry; 2006 May; 67(5):831-2. PubMed ID: 16841634 [No Abstract] [Full Text] [Related]
5. The NIMH-CATIE Schizophrenia Study: what did we learn? Lieberman JA; Stroup TS Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492 [No Abstract] [Full Text] [Related]
6. Lessons from each drug trial. Marder SR Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457 [No Abstract] [Full Text] [Related]
7. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Heinrichs RW Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745 [No Abstract] [Full Text] [Related]
8. Why do indiviuals with schizophrenia drop out of observational clinical trials? Hofer A; Radner V; Edlinger M; Kemmler G; Rettenbacher MA; Fleischhacker WW Psychiatry Res; 2017 Oct; 256():1-5. PubMed ID: 28609646 [TBL] [Abstract][Full Text] [Related]
9. Comparison of clozapine and risperidone. Hamer RM; Simpson PM Am J Psychiatry; 2000 Feb; 157(2):310. PubMed ID: 10671435 [No Abstract] [Full Text] [Related]
11. [Adherence to neuroleptic treatment of schizophrenic patients]. Blondiaux I; Alagille M; Ginestet D Encephale; 1988; 14(6):431-8. PubMed ID: 2906607 [TBL] [Abstract][Full Text] [Related]
12. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond. Nasrallah HA J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521 [No Abstract] [Full Text] [Related]
13. [Risk factors for treatment adherence in patients with schizophrenia: case-control study]. Aarab C; Elghazouani F; Aalouane R; Rammouz I Pan Afr Med J; 2015; 20():273. PubMed ID: 26161196 [TBL] [Abstract][Full Text] [Related]
14. Factors which can make patients difficult to treat. Kane JM Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650 [No Abstract] [Full Text] [Related]
15. Schizophrenia: recent advances in psychopharmacology. Sharma T Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500 [No Abstract] [Full Text] [Related]
16. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718 [TBL] [Abstract][Full Text] [Related]
17. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Möller HJ Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):371-2. PubMed ID: 16382376 [No Abstract] [Full Text] [Related]
20. The case for long-acting antipsychotic agents in the post-CATIE era. Nasrallah HA Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]